Management of vaginal cancer requires an individualized approach, considering patient preferences, the disease stage, and prognostic factors, including HPV status [45], p16 expression, p53 mutation status [46,47], tumor size, FIGO stage, lymph node involvement, and response to primary treatment [51]. This evidence concerns the gene TP53 and neoplasm.